Thyroid Gland Carcinoma

These findings indicate statistical associations rather than causal mechanisms, highlighting the need for further experimental validation. The results provide a foundation for targeted immunotherapy strategies in THCA treatment.

177Lu-therapies are restricted to 7 countries, and the availability of [131I]MIBG remains limited...Sustained investment in facilities, training, and regulatory frameworks is essential to achieve equitable access to care. IAEA's regional anchor centers as part of the Rays of Hope initiative exemplifies strategic capacity building, collaboration, and knowledge sharing in the region.

Tregs were increased and activated in DTC tumor tissue, indicating that they play an important role in creating an immunosuppressive microenvironment in DTC. The results suggest that eTreg-depletion immunotherapy using an anti-CCR4 antibody (mogamulizumab) might be effective for treating DTC.

P2, N=13, Terminated, Sidney Kimmel Cancer Center at Thomas Jefferson University | Completed --> Terminated; Poor accrual

This is the first study to identify RET fusion positivity as an independent OLNM risk factor in cN0 PTC. The developed RF model demonstrates moderate predictive performance for OLNM risk and provides a framework for integrating clinical, sonographic, and molecular data, and is deployed as a web calculator (https://predictingoccultlymphnodemetastasis.shinyapps.io/web3/).

Knockdown of APOL1 in THCA cells results in promoted proliferation and migration. Additionally, APOL1 may regulate ICI in the THCA microenvironment.

When two markers were combined, the AUC increased to 0.785 (sensitivity 70.6% and specificity 87.4%; P<0.001). Our results suggest that the combination of serum GAL-3 and Ki-67 may serve as a useful adjunct to existing diagnostic methods of thyroid cancer, such as ultrasonography and fine-needle aspiration biopsy (FNAB).

FN1 and CRABP1 were identified as potential molecular targets in thyroid cancer. These genes influence tumor progression, immune response, and patient prognosis, offering new insights for early diagnosis and personalized treatment strategies.

CMTC is usually closely related to FAP. It requires clinical attention, and the patient's intestinal condition still needs to be closely monitored after surgery.

Our two DUXAP10-CRISPRi cell lines significantly reduced the rapid growth and metastatic behaviors characteristic of ATC, affecting proliferation, viability, clonogenicity, apoptosis, invasion, migration, tumorigenesis, and metastasis. Thus, DUXAP10 is a proposed prognostic marker and therapeutic target for ATC disease propagation and progression.

These findings support evaluation of translational strategies, such as CXCR4 inhibition, restoration of antigen presentation, and macrophage reprogramming, to convert "cold" tumors into immune-permissive lesions. Validation in larger, prospective, multicenter cohorts is required.

Our findings suggest a possible association between PTX3 and aggressive TC, particularly ATC. Further studies are needed to validate these findings and elucidate the cellular origin and functional role of PTX3.